29 sep 25   cambridge cognition - exercise of options and total voting rights cambridge cognition holdings plc | cog | 40.0 1.0 2.6% | mkt cap: 18.4m    rns number : 1073b cambridge cognition holdings plc 29 september 2025     29 september 2025 cambridge cognition holdings plc ("cambridge cognition", the "company" or the "group") exercise of options and total voting rights cambridge cognition holdings plc (aim: cog), the brain health software group specialising in digital health products that advance brain health research and treatment, announces that it has issued and allotted 589,287 new ordinary shares of 1 pence each in the capital of the company (the "new ordinary shares") following an exercise of share options. application has been made to the london stock exchange for the new ordinary shares to be admitted to trading on aim, with dealings expected to commence on 30 september 2025 ("admission"). following admission, the company will have a total of 46,629,700 ordinary shares in issue. shareholders may use this figure of 46,629,700 ordinary shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the company under the fca's disclosure guidance and transparency rules.   enquiries:   cambridge cognition holdings plc rob baker, joint managing director and chief operating officer     tel: 012 2381 0700 press@camcog.com panmure liberum limited (nomad and joint broker) will goode / freddy crossley / mark rogers rupert dearden     tel: 020 7886 2968 (corporate finance) (corporate broking) dowgate capital limited (joint broker) david poutney / amber higgs     tel: 020 3903 7715      notes to editors   about cambridge cognition   cambridge cognition is a brain health software group specialising in digital health products that advance brain health research and treatment. built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. the company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts.  the company has identified four market sectors: ·      clinical studies for new pharmaceuticals; ·      academic research for scientists to understand cns disorders; ·      healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and, ·      consumer health & wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health. for further information, visit: www.cambridgecognition.com   end         this information is provided by rns, the news service of the london stock exchange. rns is approved by the financial conduct authority to act as a primary information provider in the united kingdom. terms and conditions relating to the use and distribution of this information may apply. for further information, please contact rns@lseg.com or visit www.rns.com.  rns may use your ip address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. for further information about how rns and the london stock exchange use the personal data you provide us, please see our privacy policy.   end   ioepkfbnobkddcb return to news summary

Label: Neutral